Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aytu BioScience Inc

Current price
2.85 USD -0.03 USD (-1.04%)
Last closed 2.87 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 16 839 900 USD
Yield for 12 month +56.59 %
21.11.2021 - 28.11.2021

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado. Address: Denver Corporate Center III, Denver, CO, United States, 80237

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price


P/E ratio

Dividend Yield

Current Year

+107 399 000 USD

Last Year

+96 669 000 USD

Current Quarter

+17 993 000 USD

Last Quarter

+22 934 000 USD

Current Year

+66 632 000 USD

Last Year

+52 283 000 USD

Current Quarter

+11 693 000 USD

Last Quarter

+16 203 000 USD

Key Figures AYTU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 9 893 000 USD
Operating Margin TTM -12.34 %
PE Ratio
Return On Assets TTM 0.66 %
PEG Ratio
Return On Equity TTM -38.18 %
Wall Street Target Price 8 USD
Revenue TTM 93 758 000 USD
Book Value 5.53 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -20.9 %
Dividend Yield
Gross Profit TTM 66 632 000 USD
Earnings per share -2.4 USD
Diluted Eps TTM -2.4 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -14.6 %

Dividend Analytics AYTU

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AYTU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:20
Payout Ratio
Last Split Date 06.01.2023
Dividend Date 09.12.2020

Stock Valuation AYTU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 5.7803
Enterprise Value Revenue 0.128
Price Sales TTM 0.1634
Enterprise Value EBITDA 4.0736
Price Book MRQ 0.4898

Financials AYTU

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AYTU

For 52 weeks

1.38 USD 3.5 USD
50 Day MA 3.05 USD
Shares Short Prior Month 419 354
200 Day MA 2.74 USD
Short Ratio 25.87
Shares Short 463 349
Short Percent 9.69 %

Dynamics of changes in the value of assets




212.49 USD Apple Inc -1.32 (-0.62%)
Detailed analytics

ETF funds



13.36 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) -0.53 (-3.54%)
Detailed analytics



2332.52 USD Gold +27.54 (+1.2%)
Detailed analytics